PRNewswire, 19 January 2021
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that executives of the Company will speak at the 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe (“CDP Europe”). CDP Europe will be held virtually from January 19-21, 2021. Michael Woudenberg – Vice President, Chemistry, Manufacturing & Controls, Karen Long – Senior Director, Drug Development, and Prof. Mauro Maccarrone PhD – Scientific Advisor to InMed will all be featured as expert speakers at the event.
